| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/22/2008 | US20080119407 Vitamin D Receptor Modulators |
| 05/22/2008 | US20080119404 angiopoietin-related growth factor used as antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent; polypeptides |
| 05/22/2008 | US20080119403 Haparin-Binding Protein Modified with Heparan Sulfate Sugar Chains, Process for Producing the Same and Pharmaceutical Compositions Containing the Same |
| 05/22/2008 | US20080119402 Compositions and methods for the inhibition of dishevelled proteins |
| 05/22/2008 | US20080119401 A polypeptide produced by the parathyroid glands using such analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis |
| 05/22/2008 | US20080119391 Comprising hydrolyzed gelatin/tryptophan and ingestible carrier; for decubitus ulcers/bariatric surgery |
| 05/22/2008 | US20080119389 EGCG, a protein hydrolysate and Coenzyme Q-10; orEGCG, a protein hydrolysate and resveratrol; orEGCG, a protein hydrolysate, ligustilide or other phthalides or herbal extracts containing ligustilide or other phthalides, and Coenzyme Q-10; antidiabetic agent ( insulin or non-insulin dependent diabetes) |
| 05/22/2008 | US20080119386 Nutritional formula for athletes' recovery |
| 05/22/2008 | US20080118586 Medicated cream for topical application |
| 05/22/2008 | US20080118580 plant extracts contains terpenes, plant extracts, and cinnamic acid, use as fungicide for textile treatment; fucoidine, anethol, geraniol, farnesol or farnesol acid; low concentrations and reduce side-effects |
| 05/22/2008 | US20080118579 treating a lesion with a bioactive glass of particles or fibers; improve vascularisation and preventing avascular fibrosis; drug free |
| 05/22/2008 | US20080118576 Prediction of an agent's or agents' activity across different cells and tissue types |
| 05/22/2008 | US20080118571 Modified release analgesic suspensions |
| 05/22/2008 | US20080118570 Polymer coated drug-ion exchange resins and methods |
| 05/22/2008 | US20080118567 Medicaments for Chemotherapeutic Treatment of Disease |
| 05/22/2008 | US20080118566 Micronizing mometasone furoate and lactose particles, wherein at least one has a convertible amorphous content, homogenizing, agglomerating, converting the amorphous to crystalline |
| 05/22/2008 | US20080118564 Pharmaceutical Composition Containing Candesartan Cilexetil as Lipophilic Crystalline Substance |
| 05/22/2008 | US20080118563 Preparation of Chitin and Derivatives Thereof For Cosmetic and Therapeutic Use |
| 05/22/2008 | US20080118562 Encapsulated by a biocompatible polymer shell; decreased toxicity of anticarcinogenic agents; side effect reduction |
| 05/22/2008 | US20080118560 Spray congealed 5-amido-7-benzyl(oxy or amino)imidazo[1,2-a]pyridines, at least one each of hydrophilic and hydrophobic matrix formers; antisecretory agents with improved water solubility, bioavailability and pharmacokinetics |
| 05/22/2008 | US20080118559 Pharmaceutical Composition Containing an Anti-Nucleating Agent |
| 05/22/2008 | US20080118558 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid [2'-hydroxy-2'-(3''-hydroxy-phenyl)-ethyl]-N-methyl-amide; topical analgesics and antipruritic and antitussive agents for disorders caused by kidney failure or cholestatic jaundice |
| 05/22/2008 | US20080118557 For once-a-day oral administration; improved solubility and bioavailability; side effect reduction |
| 05/22/2008 | US20080118556 Tablets or capsules with an outer controlled release layer preferably comprising methacrylate-based Eudragits"; one inner portion is quick release and the other portion is sustained release |
| 05/22/2008 | US20080118555 A lactose-based excipient and a pharmaceutically acceptable filler; basic salt-free; storage stability |
| 05/22/2008 | US20080118554 Controlled release forms of fexofenadine and pseudoephedrine; once-daily or twice-daily dosages |
| 05/22/2008 | US20080118553 Tannate salt form of polypeptide mixtures, their preparation and use |
| 05/22/2008 | US20080118549 Sustained release intraocular implants and methods for treating ocular vasculopathies |
| 05/22/2008 | US20080118548 Associated with diabetes; implanting an alpha-2 adrenergic receptor agonist, such as brimonidine, associated with a biodegradable polymer matrix; hypotensive agents, antiischemic agents; glaucoma |
| 05/22/2008 | US20080118547 Associated with diabetes; implanting an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix; hypotensive agents, antiischemic agents |
| 05/22/2008 | US20080118544 Drug releasing coatings for medical devices |
| 05/22/2008 | US20080118521 Using short intefering nucleotide sequences specific to helix-loop-helix protein (HEY-1) to treat and prevent osteoprosis and bone disorders; gene expression inhibition; antisense agents |
| 05/22/2008 | US20080118518 Cancer stem cell-targeted cancer therapy |
| 05/22/2008 | US20080118510 Vegf-related protein |
| 05/22/2008 | US20080118509 For directly inducing cell death without immune effector cells; antigens |
| 05/22/2008 | US20080118499 Using concentration of golgi-localized, gamma adaptin ear-containing, ARF-binding (GGA) as diagnostic indicator of beta-site amyloid precursor protein cleaving enzyme (BACE) activity and prognostic tool for detection of cardiovascular, nervous sytem and cell proliferative disorders |
| 05/22/2008 | US20080118497 Using presence of single nucleotide polymorphism in transient receptor potential channel gene(TRPC) as diagnostic/prognostic tool in detecting idiopathic pulmonary arterial hypertension (IPAH) |
| 05/22/2008 | US20080118495 Using avian cells as screening tools in monitoring and/or identifying viricidal agents |
| 05/22/2008 | US20080118493 Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity |
| 05/22/2008 | US20080118490 Combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements |
| 05/22/2008 | US20080118488 Multiple antioxidant micronutrients in the management of diabetes mellitus |
| 05/22/2008 | US20080118487 Cell growth factor polypeptide for use in enhancing muscle growth and treatment muscular disorders |
| 05/22/2008 | US20080118466 Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers |
| 05/22/2008 | US20080118462 Biomarkers for Melanoma |
| 05/22/2008 | US20080118459 Eraser composition for de-flakes |
| 05/22/2008 | US20080118458 Agent containing L-Carnitine or L-Carnitine derivatives and at least one other specific substance |
| 05/22/2008 | US20080118453 Calcitriol with clobetasol 17-propionate; non-aqueous nail varnish for treatment of nail psoriasis; local application of the treatment without systemic exposure; well tolerated; gradual release of active ingredients |
| 05/22/2008 | US20080118449 Cosmetic formulations of piceatannol and retinoids and methods of use thereof |
| 05/22/2008 | US20080118441 Nutraceutical; omega fatty acids; mucilaginous fiber; no glutamine; gastroesophageal reflux disease, heartburn, acid indigestion, constipation, irritable bowel syndrome |
| 05/22/2008 | US20080118436 Pathological Animal Model For Non-Alcoholic Fatty Hepatitis |
| 05/22/2008 | US20080118434 Genes Commonly Regulated by Different Classes of Antidepressants |
| 05/22/2008 | US20080117422 Methods and devices for testing germicide activity |
| 05/22/2008 | US20080115782 Pressurised metered dose inhalers (mdi) |
| 05/22/2008 | CA2705785A1 Use of lipid conjugates in the treatment of diseases or disorders of the eye |
| 05/22/2008 | CA2702694A1 Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator |
| 05/22/2008 | CA2701959A1 Inhibitors of kinase activity |
| 05/22/2008 | CA2693918A1 Matrix-embedded compositions having organic acids and fatty acids |
| 05/22/2008 | CA2678225A1 Transnasal anticonvulsive pharmaceutical composition |
| 05/22/2008 | CA2670260A1 Thiophene analogues for the treatment or prevention of flavivirus infections |
| 05/22/2008 | CA2670259A1 Compounds, compositions and methods for controlling invertebrate pests |
| 05/22/2008 | CA2669969A1 Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb3, hsdl2 and/or ldb2 |
| 05/22/2008 | CA2669917A1 Aminopyrrolidines as chemokine receptor antagonists |
| 05/22/2008 | CA2669884A1 Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| 05/22/2008 | CA2669874A1 Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| 05/22/2008 | CA2669867A1 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
| 05/22/2008 | CA2669860A1 New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| 05/22/2008 | CA2669853A1 Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents |
| 05/22/2008 | CA2669832A1 Improved methods and compositions for wound healing |
| 05/22/2008 | CA2669820A1 Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer |
| 05/22/2008 | CA2669767A1 Progesterone receptor antagonists |
| 05/22/2008 | CA2669763A1 Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| 05/22/2008 | CA2669704A1 Sulfoximines as kinase inhibitors |
| 05/22/2008 | CA2669687A1 Phthalazine derivatives |
| 05/22/2008 | CA2669686A1 7-substituted purine derivatives for immunosuppression |
| 05/22/2008 | CA2669670A1 Nitrogen-containing heterocyclic compounds and methods of use thereof |
| 05/22/2008 | CA2669635A1 Piperidine derivative or salt thereof |
| 05/22/2008 | CA2669607A1 Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
| 05/22/2008 | CA2669596A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 05/22/2008 | CA2669594A1 Clotrimazol for treating staphylococcal infections |
| 05/22/2008 | CA2669591A1 Treatment of multi-drug resistant bacterial infections |
| 05/22/2008 | CA2669539A1 Topical compositions comprising polyhydroxy acids and/or lactones for improved cutaneous effects of oxidative therapeutic drugs |
| 05/22/2008 | CA2669520A1 Methods of treating cancer using sirna molecules directed against cd24 |
| 05/22/2008 | CA2669489A1 Liquid pharmaceutical compositions comprising a bisphosphonate compound |
| 05/22/2008 | CA2669488A1 Pharmaceutical compositions comprising a bisphosphonate compound |
| 05/22/2008 | CA2669427A1 Process for the synthesis of moxifloxacin hydrochloride |
| 05/22/2008 | CA2669396A1 New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate |
| 05/22/2008 | CA2669395A1 Crystalline form of tiotropium bromide and urea |
| 05/22/2008 | CA2669357A1 Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 05/22/2008 | CA2669326A1 Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists |
| 05/22/2008 | CA2669310A1 Hepatitis c virus inhibitors |
| 05/22/2008 | CA2669246A1 Use of gabapentin and pregabalin prodrugs for treating tinnitus |
| 05/22/2008 | CA2669230A1 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof |
| 05/22/2008 | CA2669221A1 Heterocyclic derivatives as cetp inhibitors |
| 05/22/2008 | CA2669158A1 Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
| 05/22/2008 | CA2669131A1 Polymorphisms predictive of anthracycline-induced cardiotoxicity |
| 05/22/2008 | CA2669123A1 Acat inhibitors and their use in the prevention or treatment of fibrosis |
| 05/22/2008 | CA2669112A1 Substituted 4-imidazoles |
| 05/22/2008 | CA2669080A1 Cannabinoid receptor modulators |
| 05/22/2008 | CA2668885A1 Method for administering weight loss medications |
| 05/22/2008 | CA2668884A1 Layered pharmaceutical formulations |